Pages that link to "Q30249335"
Jump to navigation
Jump to search
The following pages link to Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. (Q30249335):
Displaying 6 items.
- Sorafenib-Associated Heart Failure Complicated by Cardiogenic Shock after Treatment of Advanced Stage Hepatocellular Carcinoma: A Clinical Case Discussion (Q33659820) (← links)
- Non-Targeted Metabolomics Analysis of the Effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Heart, Muscle, Liver and Serum Metabolism In Vivo. (Q41666775) (← links)
- Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. (Q45073135) (← links)
- Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis. (Q47699276) (← links)
- Genetic predisposition to bevacizumab-induced hypertension (Q47713143) (← links)
- Exaggerated Cardiotoxicity of Sunitinib in Stressed 3-Dimensional Heart Muscles (Q90652928) (← links)